Caroline Seymour

Articles

The Future of Cancer Immunotherapy Lies in Combinational Approaches

May 6th 2021

Arsen Osipov, MD, discusses the potential for ongoing research with immunotherapeutic approaches in gastrointestinal malignancies, including CAR T-cell therapy, bispecific T-cell engagers, and vaccines.

Providing Nursing Insight Into the Management of irAEs in Lung Cancer

May 4th 2021

Marianne Davies, NP, DNP, MSN, BSN, discussed the potential severity of immune-related adverse effects and detailed recommended management strategies for patients receiving checkpoint inhibitors, especially in lung cancer.

Thermal Ablation Shown to Be Safe, Effective Local Treatment in Gynecologic Cancers

April 30th 2021

Thermal ablation was shown to be a safe and effective treatment for patients with localized gynecologic tumors in the lungs, abdomen, and pelvis, according to findings from a retrospective analysis published in the Journal of Vascular and Interventional Radiology.

FDA Panel Opposes Nivolumab for Second-line Advanced HCC

April 29th 2021

In a 5 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted to oppose maintaining the accelerated approval of nivolumab monotherapy for patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib.

ODAC Unanimously Backs Pembrolizumab for Second-line Advanced HCC

April 29th 2021

In an 8 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee voted to support the accelerated approval of pembrolizumab monotherapy for patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib.

ODAC Votes Against Pembrolizumab for PD-L1+ Gastric/GEJ Cancer

April 29th 2021

In a 6 to 2 vote, the FDA’s Oncologic Drugs Advisory Committee voted against maintaining the accelerated approval of pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more lines of therapy.

FDA Panel Endorses Atezolizumab for Frontline Metastatic Urothelial Cancer

April 28th 2021

In a 10 to 1 vote, the FDA’s Oncologic Drugs Advisory Committee voted to support the accelerated approval of atezolizumab for the frontline treatment of patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma.

ODAC Votes in Favor of Pembrolizumab Approval in Frontline Metastatic Urothelial Cancer

April 28th 2021

In a 5 to 3 vote, the FDA’s Oncologic Drugs Advisory Committee voted to uphold the accelerated approval of pembrolizumab for the frontline treatment of patients with cisplatin-ineligible and carboplatin-ineligible locally advanced or metastatic urothelial carcinoma.

Risk-Based Triaged Mammograms Demonstrate Success During Periods of Reduced Capacity

April 28th 2021

Triaging individuals with the highest likelihood of cancer detection with their clinical indication and individual risk factors during periods of reduced capacity could be an efficient way of identifying the most cancers with the least examinations compared with a non–risk-based approach.

FDA Panel Supports Atezolizumab/Nab-Paclitaxel Combo for PD-L1+ Metastatic TNBC

April 27th 2021

The FDA's Oncologic Drugs Advisory Committee voted 7 to 2 in support of maintaining the indication of atezolizumab in combination with nab-paclitaxel as a treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors are PD-L1 positive.